Combined Model of Frameshift Mutations and Tumor Mutation Burden in Predicting Preliminary Response to Immune Checkpoint Inhibitors in NSCLC

被引：1
|
作者：
Zhou, Huaqiang [1 ,2 ,3 ]
Liu, Jiaqing [1 ,2 ,3 ,4 ]
Zhang, Yaxiong [1 ,2 ,3 ]
Fang, Wenfeng [1 ,2 ,3 ]
Zhang, Li [1 ,2 ,3 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China
[2] State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
[3] Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China
[4] Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 12期
基金：
国家重点研发计划;
关键词：
D O I：
10.1016/j.jtho.2019.06.031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E271 / E273
页数：4
相关论文
共 50 条
  • [1] Association of KMT2C/D Mutations with Tumor Mutation Burden and Response to Immune Checkpoint Inhibitors in NSCLC
    Liu, R.
    Niu, Y.
    Ma, T.
    Yuan, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S546 - S546
  • [2] Combined model of frameshift mutations and TMB in predicting response to immunotherapy in NSCLC
    Zhou, H.
    Liu, J.
    Zhang, Y.
    Fang, W.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] Frameshift mutations (Fsindel) complement tumor mutation burden (TMB) in predicting survival after immune checkpoint inhibitors (ICI) in a pancancer analysis.
    Florou, Vaia
    Park, Wungki
    Hosein, Peter Joel
    Wilky, Breelyn A.
    Trent, Jonathan C.
    Lopes, Gilberto
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
    Moeckel, Camille
    Bakhl, Katrina
    Georgakopoulos-Soares, Ilias
    Zaravinos, Apostolos
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)
  • [5] Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
    Zheng, Ming
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [6] Tumor mutation burden predicts response and survival to immune checkpoint inhibitors: a meta-analysis
    Wan, Linghong
    Wang, Zhi
    Xue, Jinmin
    Yang, Huaju
    Zhu, Yuxi
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (09) : 5437 - 5449
  • [7] Predicting response to immune checkpoint therapy using an mutation burden threshold
    Panda, Anshuman
    Betigeri, Anil
    Subramanian, Kalyanasundaram
    Hirshfield, Kim
    Rodriguez, Lorna
    Ganesan, Shridar
    Bhanot, Gyan
    CANCER RESEARCH, 2016, 76
  • [8] Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
    Florou, Vaia
    Floudas, Charalampos S.
    Maoz, Asaf
    Naqash, Abdul Rafeh
    Norton, Carter
    Tan, Aik Choon
    Sokol, Ethan S.
    Frampton, Garrett
    Soares, Heloisa P.
    Puri, Sonam
    Swami, Umang
    Wilky, Breelyn
    Hosein, Peter
    Trent, Jonathan
    Lopes, Gilberto de Lima
    Park, Wungki
    Garrido-Laguna, Ignacio
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (08)
  • [9] DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden
    Hsiehchen, David
    Hsieh, Antony
    Samstein, Robert M.
    Lu, Tianshi
    Beg, Muhammad S.
    Gerber, David E.
    Wang, Tao
    Morris, Luc G. T.
    Zhu, Hao
    CELL REPORTS MEDICINE, 2020, 1 (03)
  • [10] BASELINE GLYCOLYTIC TUMOR BURDEN PREDICTS RESPONSE AND SURVIVAL IN NSCLC AND MELANOMA PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS
    Silva, Saulo
    Wanderley, Carlos Wagner
    Marin, Jose Flavio
    De Macedo, Mariana
    Nascimento, Ellen
    Antonacio, Fernanda
    Cunha, Fernando
    de Castro, Gilberto
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A62 - A63
12345